BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Ménard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996;97:839-44. [PMID: 8609242 DOI: 10.1172/JCI118484] [Cited by in Crossref: 252] [Cited by in F6Publishing: 68] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Rasoul S, Carretero OA, Peng H, Cavasin MA, Zhuo J, Sanchez-Mendoza A, Brigstock DR, Rhaleb NE. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens 2004;22:593-603. [PMID: 15076166 DOI: 10.1097/00004872-200403000-00023] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 3.8] [Reference Citation Analysis]
2 Shen XZ, Ong FS, Bernstein EA, Janjulia T, Blackwell WL, Shah KH, Taylor BL, Gonzalez-Villalobos RA, Fuchs S, Bernstein KE. Nontraditional roles of angiotensin-converting enzyme. Hypertension 2012;59:763-8. [PMID: 22353608 DOI: 10.1161/HYPERTENSIONAHA.111.188342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
3 Dive V, Cotton J, Yiotakis A, Michaud A, Vassiliou S, Jiracek J, Vazeux G, Chauvet MT, Cuniasse P, Corvol P. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc Natl Acad Sci U S A 1999;96:4330-5. [PMID: 10200262 DOI: 10.1073/pnas.96.8.4330] [Cited by in Crossref: 126] [Cited by in F6Publishing: 109] [Article Influence: 5.5] [Reference Citation Analysis]
4 Zhuo JL, Carretero OA, Peng H, Li XC, Regoli D, Neugebauer W, Rhaleb NE. Characterization and localization of Ac-SDKP receptor binding sites using 125I-labeled Hpp-Aca-SDKP in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol. 2007;292:H984-H993. [PMID: 17028162 DOI: 10.1152/ajpheart.00776.2006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
5 Xu H, Yang F, Sun Y, Yuan Y, Cheng H, Wei Z, Li S, Cheng T, Brann D, Wang R. A new antifibrotic target of Ac-SDKP: inhibition of myofibroblast differentiation in rat lung with silicosis. PLoS One 2012;7:e40301. [PMID: 22802960 DOI: 10.1371/journal.pone.0040301] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
6 Shen XZ, Bernstein KE. The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis. Cell Cycle 2011;10:1363-9. [PMID: 21441775 DOI: 10.4161/cc.10.9.15444] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
7 Moulder JE, Cohen EP, Fish BL. Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation. Radiat Res 2011;175:29-36. [PMID: 21175344 DOI: 10.1667/RR2400.1] [Cited by in Crossref: 55] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
8 Worou ME, Liao TD, D'Ambrosio M, Nakagawa P, Janic B, Peterson EL, Rhaleb NE, Carretero OA. Renal protective effect of N-acetyl-seryl-aspartyl-lysyl-proline in dahl salt-sensitive rats. Hypertension 2015;66:816-22. [PMID: 26324505 DOI: 10.1161/HYPERTENSIONAHA.115.05970] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
9 Alves MT, Vilaça SS, Carvalho Md, Fernandes AP, Dusse LM, Gomes KB. Resistance of dialyzed patients to erythropoietin. Rev Bras Hematol Hemoter 2015;37:190-7. [PMID: 26041422 DOI: 10.1016/j.bjhh.2015.02.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
10 Cole J, Ertoy D, Lin H, Sutliff RL, Ezan E, Guyene TT, Capecchi M, Corvol P, Bernstein KE. Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest 2000;106:1391-8. [PMID: 11104792 DOI: 10.1172/JCI10557] [Cited by in Crossref: 117] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
11 Ma LJ, Fogo AB. PAI-1 and kidney fibrosis. Front Biosci (Landmark Ed) 2009;14:2028-41. [PMID: 19273183 DOI: 10.2741/3361] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
12 Liao TD, Yang XP, D'Ambrosio M, Zhang Y, Rhaleb NE, Carretero OA. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research. Hypertension 2010;55:459-67. [PMID: 20026760 DOI: 10.1161/HYPERTENSIONAHA.109.144568] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
13 Urbanek K, Quaini F, Tasca G, Torella D, Castaldo C, Nadal-Ginard B, Leri A, Kajstura J, Quaini E, Anversa P. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc Natl Acad Sci USA. 2003;100:10440-10445. [PMID: 12928492 DOI: 10.1073/pnas.1832855100] [Cited by in Crossref: 359] [Cited by in F6Publishing: 298] [Article Influence: 18.9] [Reference Citation Analysis]
14 Nitta K, Shi S, Nagai T, Kanasaki M, Kitada M, Srivastava SP, Haneda M, Kanasaki K, Koya D. Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen. Biomed Res Int 2016;2016:9172157. [PMID: 27088094 DOI: 10.1155/2016/9172157] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
15 Nakagawa P, Liu Y, Liao TD, Chen X, González GE, Bobbitt KR, Smolarek D, Peterson EL, Kedl R, Yang XP, Rhaleb NE, Carretero OA. Treatment with N-acetyl-seryl-aspartyl-lysyl-proline prevents experimental autoimmune myocarditis in rats. Am J Physiol Heart Circ Physiol 2012;303:H1114-27. [PMID: 22923621 DOI: 10.1152/ajpheart.00300.2011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
16 Hilzendeger AM, Morais RL, Todiras M, Plehm R, da Costa Goncalves A, Qadri F, Araujo RC, Gross V, Nakaie CR, Casarini DE, Carmona AK, Bader M, Pesquero JB. Leptin regulates ACE activity in mice. J Mol Med (Berl) 2010;88:899-907. [PMID: 20614101 DOI: 10.1007/s00109-010-0649-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
17 Danilov SM, Wade MS, Schwager SL, Douglas RG, Nesterovitch AB, Popova IA, Hogarth KD, Bhardwaj N, Schwartz DE, Sturrock ED, Garcia JG. A novel angiotensin I-converting enzyme mutation (S333W) impairs N-domain enzymatic cleavage of the anti-fibrotic peptide, AcSDKP. PLoS One 2014;9:e88001. [PMID: 24505347 DOI: 10.1371/journal.pone.0088001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
18 Peng H, Carretero OA, Raij L, Yang F, Kapke A, Rhaleb NE. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension 2001;37:794-800. [PMID: 11230375 DOI: 10.1161/01.hyp.37.2.794] [Cited by in Crossref: 71] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
19 Alhenc-Gelas F, Bouby N, Girolami JP. Kallikrein/K1, Kinins, and ACE/Kininase II in Homeostasis and in Disease Insight From Human and Experimental Genetic Studies, Therapeutic Implication. Front Med (Lausanne) 2019;6:136. [PMID: 31316987 DOI: 10.3389/fmed.2019.00136] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
20 Akif M, Masuyer G, Bingham RJ, Sturrock ED, Isaac RE, Acharya KR. Structural basis of peptide recognition by the angiotensin-1 converting enzyme homologue AnCE from Drosophila melanogaster. FEBS J 2012;279:4525-34. [PMID: 23082758 DOI: 10.1111/febs.12038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
21 Peng H, Xu J, Yang XP, Kassem KM, Rhaleb IA, Peterson E, Rhaleb NE. N-acetyl-seryl-aspartyl-lysyl-proline treatment protects heart against excessive myocardial injury and heart failure in mice. Can J Physiol Pharmacol 2019;97:753-65. [PMID: 30998852 DOI: 10.1139/cjpp-2019-0047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Lin CX, Rhaleb NE, Yang XP, Liao TD, D'Ambrosio MA, Carretero OA. Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 2008;295:H1253-61. [PMID: 18641275 DOI: 10.1152/ajpheart.00481.2008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
23 Guirguis K. Anaemia in heart failure patients: the prevalence of haematinic deficiencies and the role of ACE inhibitors and aspirin doses as risk factors. Pharm Pract (Granada) 2019;17:1406. [PMID: 31015880 DOI: 10.18549/PharmPract.2019.1.1406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 Guang C, Phillips RD, Jiang B, Milani F. Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system. Arch Cardiovasc Dis. 2012;105:373-385. [PMID: 22800722 DOI: 10.1016/j.acvd.2012.02.010] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 7.6] [Reference Citation Analysis]
25 Rhaleb NE, Peng H, Yang XP, Liu YH, Mehta D, Ezan E, Carretero OA. Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension. Circulation 2001;103:3136-41. [PMID: 11425781 DOI: 10.1161/01.cir.103.25.3136] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
26 Maheshwari M, Romero CA, Monu SR, Kumar N, Liao TD, Peterson EL, Carretero OA. Renal Protective Effects of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) in Obese Rats on a High-Salt Diet. Am J Hypertens 2018;31:902-9. [PMID: 29722788 DOI: 10.1093/ajh/hpy052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Mnguni AT, Engel ME, Borkum MS, Mayosi BM. The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis. PLoS One 2015;10:e0143338. [PMID: 26656271 DOI: 10.1371/journal.pone.0143338] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Wang D, Carretero OA, Yang XY, Rhaleb NE, Liu YH, Liao TD, Yang XP. N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. Am J Physiol Heart Circ Physiol 2004;287:H2099-105. [PMID: 15256375 DOI: 10.1152/ajpheart.00592.2004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 3.0] [Reference Citation Analysis]
29 Kanasaki M, Nagai T, Kitada M, Koya D, Kanasaki K. Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair 2011;4:25. [PMID: 22126210 DOI: 10.1186/1755-1536-4-25] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
30 Li P, Xiao HD, Xu J, Ong FS, Kwon M, Roman J, Gal A, Bernstein KE, Fuchs S. Angiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury. Am J Pathol 2010;177:1113-21. [PMID: 20651228 DOI: 10.2353/ajpath.2010.081127] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
31 Rhaleb NE, Pokharel S, Sharma U, Carretero OA. Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice. J Hypertens 2011;29:330-8. [PMID: 21052020 DOI: 10.1097/HJH.0b013e32834103ee] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
32 Yano S, Suzuki K, Iwamoto M, Urushidani Y, Yokogi H, Kusakari M, Aoki A, Sumi M, Kitamura K, Sanematsu H, Gohbara M, Imamura S, Sugimoto T. Association between erythropoietin requirements and antihypertensive agents. Nephron Clin Pract 2008;109:c33-9. [PMID: 18506108 DOI: 10.1159/000134929] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
33 Liu YH, D'Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, André S, Gabius HJ, Carretero OA. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol. 2009;296:H404-H412. [PMID: 19098114 DOI: 10.1152/aipheart.00747.2008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Isaac R, Schoofs L, Williams TA, Veelaert D, Sajid M, Corvol P, Coates D. A novel peptide-processing activity of insect peptidyl-dipeptidase A (angiotensin I-converting enzyme): the hydrolysis of lysyl-arginine and arginyl-arginine from the C-terminus of an insect prohormone peptide. Biochem J 1998;330 ( Pt 1):61-5. [PMID: 9461491 DOI: 10.1042/bj3300061] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 1.9] [Reference Citation Analysis]
35 Banu N, Panikar SS, Leal LR, Leal AR. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications. Life Sci. 2020;256:117905. [PMID: 32504757 DOI: 10.1016/j.lfs.2020.117905] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 24.0] [Reference Citation Analysis]
36 Liao TD, Nakagawa P, Janic B, D'Ambrosio M, Worou ME, Peterson EL, Rhaleb NE, Yang XP, Carretero OA. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythematosus. Am J Physiol Renal Physiol 2015;308:F1146-54. [PMID: 25740596 DOI: 10.1152/ajprenal.00039.2015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
37 Cozier GE, Lubbe L, Sturrock ED, Acharya KR. Angiotensin-converting enzyme open for business: structural insights into the subdomain dynamics. FEBS J 2021;288:2238-56. [PMID: 33067882 DOI: 10.1111/febs.15601] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Li C, Zhang L, Wang C, Teng H, Fan B, Chopp M, Zhang ZG. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke. Stroke 2019;50:2547-54. [PMID: 31387512 DOI: 10.1161/STROKEAHA.119.026212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis. World J Nephrol 2021; 10(6): 109-121 [PMID: 34909408 DOI: 10.5527/wjn.v10.i6.109] [Reference Citation Analysis]
40 Macours N, Poels J, Hens K, Francis C, Huybrechts R. Structure, evolutionary conservation, and functions of angiotensin- and endothelin-converting enzymes. Int Rev Cytol 2004;239:47-97. [PMID: 15464852 DOI: 10.1016/S0074-7696(04)39002-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
41 Hamid S, Rhaleb IA, Kassem KM, Rhaleb NE. Role of Kinins in Hypertension and Heart Failure. Pharmaceuticals (Basel) 2020;13:E347. [PMID: 33126450 DOI: 10.3390/ph13110347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
42 Douglas RG, Sharma RK, Masuyer G, Lubbe L, Zamora I, Acharya KR, Chibale K, Sturrock ED. Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors. Clin Sci (Lond) 2014;126:305-13. [PMID: 24015848 DOI: 10.1042/CS20130403] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
43 Shi Y, Zhou M, Yan J, Gong Z, Wu J, Chen Y, Chen Y. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses via MEK-ERK Signaling. Front Pharmacol 2020;11:593. [PMID: 32435194 DOI: 10.3389/fphar.2020.00593] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Peng H, Carretero OA, Brigstock DR, Oja-Tebbe N, Rhaleb NE. Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension. Hypertension 2003;42:1164-70. [PMID: 14581293 DOI: 10.1161/01.HYP.0000100423.24330.96] [Cited by in Crossref: 56] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
45 Kanasaki K, Nagai T, Nitta K, Kitada M, Koya D. N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes. Front Pharmacol 2014;5:70. [PMID: 24782774 DOI: 10.3389/fphar.2014.00070] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
46 Esther CR, Marino EM, Howard TE, Machaud A, Corvol P, Capecchi MR, Bernstein KE. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997;99:2375-85. [PMID: 9153279 DOI: 10.1172/JCI119419] [Cited by in Crossref: 208] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
47 Nitta K, Nagai T, Mizunuma Y, Kitada M, Nakagawa A, Sakurai M, Toyoda M, Haneda M, Kanasaki K, Koya D. N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFR ≥ 30 ml/min/1.73 m2. Clin Exp Nephrol 2019;23:1004-12. [PMID: 30949886 DOI: 10.1007/s10157-019-01733-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Peng H, Carretero OA, Liao TD, Peterson EL, Rhaleb NE. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension. Hypertension 2007;49:695-703. [PMID: 17283252 DOI: 10.1161/01.HYP.0000258406.66954.4f] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
49 Spowage BM, Bruce CL, Hirst JD. Interpretable correlation descriptors for quantitative structure-activity relationships. J Cheminform 2009;1:22. [PMID: 20151000 DOI: 10.1186/1758-2946-1-22] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
50 Cavasin MA, Rhaleb NE, Yang XP, Carretero OA. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 2004;43:1140-5. [PMID: 15037553 DOI: 10.1161/01.HYP.0000126172.01673.84] [Cited by in Crossref: 94] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
51 Isaac RE, Williams TA, Sajid M, Corvol P, Coates D. Cleavage of arginyl-arginine and lysyl-arginine from the C-terminus of pro-hormone peptides by human germinal angiotensin I-converting enzyme (ACE) and the C-domain of human somatic ACE. Biochem J 1997;328 ( Pt 2):587-91. [PMID: 9371719 DOI: 10.1042/bj3280587] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
52 Zhang Y, Zhang ZG, Chopp M, Meng Y, Zhang L, Mahmood A, Xiong Y. Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline. J Neurosurg 2017;126:782-95. [PMID: 28245754 DOI: 10.3171/2016.3.JNS152699] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
53 Kanasaki K. N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects. J Diabetes Investig 2020;11:516-26. [PMID: 31997585 DOI: 10.1111/jdi.13219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
54 Cao DY, Saito S, Veiras LC, Okwan-Duodu D, Bernstein EA, Giani JF, Bernstein KE, Khan Z. Role of angiotensin-converting enzyme in myeloid cell immune responses. Cell Mol Biol Lett 2020;25:31. [PMID: 32508938 DOI: 10.1186/s11658-020-00225-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Nagai T, Nitta K, Kanasaki M, Koya D, Kanasaki K. The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis. Clin Exp Nephrol 2015;19:65-74. [PMID: 24975544 DOI: 10.1007/s10157-014-1000-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
56 Kassem KM, Vaid S, Peng H, Sarkar S, Rhaleb NE. Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system? Can J Physiol Pharmacol 2019;97:589-99. [PMID: 30854877 DOI: 10.1139/cjpp-2018-0570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
57 Saka B, Sayitoğlu M, İstemihan Z, Karan MA, Erten N, Doğan Ö, Özbek U, Genç S, Taşçıoğlu C, Kalayoğlu-Beşışık S. The Role of the Local Bone Marrow Renin-Angiotensin System in Multiple Myeloma. Turk J Haematol 2019;36:178-85. [PMID: 31042345 DOI: 10.4274/tjh.galenos.2019.2018.0420] [Reference Citation Analysis]
58 Pappa M, Dounousi E, Duni A, Katopodis K. Less known pathophysiological mechanisms of anemia in patients with diabetic nephropathy. Int Urol Nephrol 2015;47:1365-72. [PMID: 26017902 DOI: 10.1007/s11255-015-1012-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
59 Yang F, Yang XP, Liu YH, Xu J, Cingolani O, Rhaleb NE, Carretero OA. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 2004;43:229-36. [PMID: 14691195 DOI: 10.1161/01.HYP.0000107777.91185.89] [Cited by in Crossref: 106] [Cited by in F6Publishing: 60] [Article Influence: 5.6] [Reference Citation Analysis]
60 Rhaleb NE, Peng H, Harding P, Tayeh M, LaPointe MC, Carretero OA. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension. 2001;37:827-832. [PMID: 11244003 DOI: 10.1161/01.HYP.37.3.827] [Cited by in Crossref: 67] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
61 Bernstein KE, Shen XZ, Gonzalez-Villalobos RA, Billet S, Okwan-Duodu D, Ong FS, Fuchs S. Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Curr Opin Pharmacol 2011;11:105-11. [PMID: 21130035 DOI: 10.1016/j.coph.2010.11.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
62 Peng H, Carretero OA, Peterson EL, Yang XP, Santra K, Rhaleb NE. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits ET-1-induced collagen production by preserving Src homology 2-containing protein tyrosine phosphatase-2 activity in cardiac fibroblasts. Pflugers Arch 2012;464:415-23. [PMID: 22968858 DOI: 10.1007/s00424-012-1150-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
63 Wong MMY, Tu C, Li Y, Perlman RL, Pecoits-Filho R, Lopes AA, Narita I, Reichel H, Port FK, Sukul N, Stengel B, Robinson BM, Massy ZA, Pisoni RL; CKDopps Investigators . Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J 2020;13:613-24. [PMID: 32905241 DOI: 10.1093/ckj/sfz091] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 8.3] [Reference Citation Analysis]
64 Ingrasciotta Y, Lacava V, Marcianò I, Giorgianni F, Tripepi G, D' Arrigo G, Chinellato A, Ugo Tari D, Santoro D, Trifirò G. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. BMC Nephrol 2019;20:359. [PMID: 31521117 DOI: 10.1186/s12882-019-1554-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
65 Peng H, Carretero OA, Vuljaj N, Liao TD, Motivala A, Peterson EL, Rhaleb NE. Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 2005;112:2436-45. [PMID: 16216963 DOI: 10.1161/CIRCULATIONAHA.104.528695] [Cited by in Crossref: 112] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
66 Sica DA, Gehr TW, Fernandez A. Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease. Drug Saf 2000;22:350-60. [PMID: 10830252 DOI: 10.2165/00002018-200022050-00003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
67 Peng H, Carretero OA, Peterson EL, Rhaleb NE. Ac-SDKP inhibits transforming growth factor-beta1-induced differentiation of human cardiac fibroblasts into myofibroblasts. Am J Physiol Heart Circ Physiol. 2010;298:H1357-H1364. [PMID: 20154264 DOI: 10.1152/ajpheart.00464.2009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
68 Liu YH, D'Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, André S, Gabius HJ, Carretero OA. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009;296:H404-12. [PMID: 19098114 DOI: 10.1152/ajpheart.00747.2008] [Cited by in Crossref: 183] [Cited by in F6Publishing: 166] [Article Influence: 13.1] [Reference Citation Analysis]